ASR Vermogensbeheer N.V. Buys Shares of 9,789 Axon Enterprise, Inc (NASDAQ:AXON)

Key Points

• ASR Vermogensbeheer N.V. acquired approximately 9,789 shares of Axon Enterprise, Inc. valued at around $5.148 million in the first quarter.
• Axon Enterprise reported a 32.6% year-over-year revenue increase with earnings per share (EPS) of $2.12, surpassing analyst expectations.
• Recent analyst ratings for Axon Enterprise indicate a positive outlook, with multiple firms raising their price targets, some up to $1,000, all maintaining a "buy" rating.

ASR Vermogensbeheer N.V. bought a new stake in shares of Axon Enterprise, Inc (NASDAQ:AXON - Free Report) in the 1st quarter, according to its most recent filing with the Securities & Exchange Commission. The fund bought 9,789 shares of the biotechnology company's stock, valued at approximately $5,148,000.

Several other hedge funds have also bought and sold shares of AXON. TCTC Holdings LLC lifted its position in Axon Enterprise by 75.0% during the first quarter. TCTC Holdings LLC now owns 56 shares of the biotechnology company's stock valued at $29,000 after purchasing an additional 24 shares during the last quarter. Fourth Dimension Wealth LLC bought a new stake in shares of Axon Enterprise in the 4th quarter worth approximately $30,000. Bartlett & CO. Wealth Management LLC lifted its holdings in shares of Axon Enterprise by 132.0% in the 1st quarter. Bartlett & CO. Wealth Management LLC now owns 58 shares of the biotechnology company's stock worth $31,000 after acquiring an additional 33 shares during the last quarter. Catalyst Capital Advisors LLC bought a new stake in shares of Axon Enterprise in the 1st quarter worth approximately $32,000. Finally, Alpine Bank Wealth Management bought a new stake in shares of Axon Enterprise in the 1st quarter worth approximately $40,000. 79.08% of the stock is currently owned by institutional investors.

Axon Enterprise Stock Up 0.8%

Shares of NASDAQ AXON opened at $870.97 on Friday. The company has a current ratio of 2.95, a quick ratio of 2.62 and a debt-to-equity ratio of 0.63. Axon Enterprise, Inc has a 12 month low of $344.00 and a 12 month high of $885.91. The firm has a market capitalization of $68.37 billion, a PE ratio of 215.05, a price-to-earnings-growth ratio of 19.36 and a beta of 1.36. The firm has a fifty day simple moving average of $772.30 and a two-hundred day simple moving average of $663.05.

Axon Enterprise (NASDAQ:AXON - Get Free Report) last issued its quarterly earnings data on Monday, August 4th. The biotechnology company reported $2.12 EPS for the quarter, topping the consensus estimate of $1.54 by $0.58. Axon Enterprise had a net margin of 13.64% and a return on equity of 6.80%. The business had revenue of $668.54 million during the quarter, compared to analyst estimates of $641.77 million. During the same period in the prior year, the business earned $1.20 EPS. The company's revenue for the quarter was up 32.6% on a year-over-year basis. Equities analysts expect that Axon Enterprise, Inc will post 5.8 earnings per share for the current year.

Analyst Upgrades and Downgrades

AXON has been the subject of a number of recent research reports. The Goldman Sachs Group boosted their price objective on shares of Axon Enterprise from $730.00 to $830.00 and gave the stock a "buy" rating in a report on Wednesday, May 14th. Raymond James Financial restated an "outperform" rating and issued a $855.00 price objective (up from $645.00) on shares of Axon Enterprise in a report on Tuesday. Bank of America boosted their price objective on shares of Axon Enterprise from $895.00 to $1,000.00 and gave the stock a "buy" rating in a report on Wednesday. Craig Hallum upgraded shares of Axon Enterprise from a "hold" rating to a "buy" rating and set a $900.00 price objective for the company in a report on Tuesday. Finally, JMP Securities boosted their price objective on shares of Axon Enterprise from $725.00 to $825.00 and gave the stock a "market outperform" rating in a report on Tuesday, July 22nd. Two analysts have rated the stock with a hold rating and thirteen have issued a buy rating to the stock. According to MarketBeat.com, the stock currently has an average rating of "Moderate Buy" and a consensus target price of $837.69.

Insiders Place Their Bets

In other Axon Enterprise news, President Joshua Isner sold 9,905 shares of the company's stock in a transaction on Wednesday, May 21st. The shares were sold at an average price of $738.03, for a total value of $7,310,187.15. Following the completion of the transaction, the president directly owned 298,809 shares in the company, valued at approximately $220,530,006.27. This represents a 3.21% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, Director Michael Garnreiter sold 5,913 shares of the company's stock in a transaction on Wednesday, June 4th. The stock was sold at an average price of $760.00, for a total transaction of $4,493,880.00. Following the completion of the transaction, the director owned 17,740 shares of the company's stock, valued at $13,482,400. This trade represents a 25.00% decrease in their ownership of the stock. The disclosure for this sale can be found here. In the last ninety days, insiders sold 34,642 shares of company stock worth $25,090,528. Company insiders own 4.40% of the company's stock.

Axon Enterprise Profile

Axon Enterprise, Inc develops, manufactures, and sells conducted energy devices (CEDs) under the TASER brand in the United States and internationally. It operates through two segments, Software and Sensors, and TASER. The company also offers hardware and cloud-based software solutions that enable law enforcement to capture, securely store, manage, share, and analyze video and other digital evidence.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.